Stocktoria
Fulcrum Therapeutics, Inc. FULC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-07-18
Fulcrum Therapeutics, Inc. statistics & valuation
Market cap$253.2M
P / B0.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -27.4% | -3945.2% | -1774.9% | -423.0% |
| Net margin | — | -12.2% | -3470.1% | -1732.4% | -421.9% |
| FCF margin | — | -3.1% | -3261.1% | -1561.2% | -418.5% |
| Return on assets | -20.4% | -3.7% | -37.8% | -48.5% | -34.4% |
| Return on equity | -21.5% | -4.0% | -41.4% | -55.2% | -38.2% |
| Current ratio | 27.40 | 22.63 | 17.71 | 12.41 | 11.77 |
| Revenue growth | -100.0% | 2752.0% | -55.8% | -66.9% | 117.2% |
Source: SEC EDGAR filings · CIK 0001680581 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.